ADmit Therapeutics
ADmit Therapeutics S.L. is a pioneering company in neurodegenerative disease diagnostics, specializing in early detection of Alzheimer's disease (AD). Their core product, the MAP-AD® Test, is a disruptive in-vitro diagnostic test that utilizes a novel epigenetic biomarker from mitochondrial DNA, analyzed through Next Generation Sequencing and Machine Learning, to predict the progression of Alzheimer's dementia even before beta-amyloid detection. This test associates mitochondrial dysfunction with cognitive changes and analyzes epigenetic blood markers, mitochondrial DNA methylation, ApoE genotype, and age for prognosis. ADmit Therapeutics aims to advance personalized medicine by enabling earlier interventions and optimizing patient selection for clinical trials. They also provide epigenetic services to pharmaceutical companies for early-stage AD clinical trials and are developing products for other neurodegenerative diseases like Lewy Body Dementia. The company holds significant certifications including ISO 13485 and accreditation from the College of American Pathologists (CAP), and has received funding from the EU's H2020 program.
ADmit Therapeutics
ADmit Therapeutics S.L. is a pioneering company in neurodegenerative disease diagnostics, specializing in early detection of Alzheimer's disease (AD). Their core product, the MAP-AD® Test, is a disruptive in-vitro diagnostic test that utilizes a novel epigenetic biomarker from mitochondrial DNA, analyzed through Next Generation Sequencing and Machine Learning, to predict the progression of Alzheimer's dementia even before beta-amyloid detection. This test associates mitochondrial dysfunction with cognitive changes and analyzes epigenetic blood markers, mitochondrial DNA methylation, ApoE genotype, and age for prognosis. ADmit Therapeutics aims to advance personalized medicine by enabling earlier interventions and optimizing patient selection for clinical trials. They also provide epigenetic services to pharmaceutical companies for early-stage AD clinical trials and are developing products for other neurodegenerative diseases like Lewy Body Dementia. The company holds significant certifications including ISO 13485 and accreditation from the College of American Pathologists (CAP), and has received funding from the EU's H2020 program.